Australia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
160.35+1.76 (+1.11%)
At close: 04:00PM EDT
160.70 +0.35 (+0.22%)
Pre-market: 08:24AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close158.59
Bid159.69 x 1000
Ask161.85 x 900
Day's range158.60 - 161.60
52-week range117.08 - 388.00
Avg. volume1,097,566
Market cap38.915B
Beta (5Y monthly)-0.08
PE ratio (TTM)3.44
EPS (TTM)46.63
Earnings date07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date02 June 2022
1y target est240.07
  • Yahoo Finance

    Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity

    Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.

  • Motley Fool

    Is This Battered Growth Stock Still a Buy After Its Latest Stumble?

    After reporting worse than anticipated second-quarter earnings on Aug. 8, shares of BioNTech (NASDAQ: BNTX) are tumbling, deepening the stock's decline to 65% over the last 12 months. The culprit is the biotech's lackluster sales of Comirnaty, its coronavirus vaccine developed in conjunction with Pfizer.

  • Motley Fool

    Why BioNTech Was Tumbling Again Today

    This isn't shaping up to be a banner week for BioNTech (NASDAQ: BNTX). The bellwether coronavirus stock took it on the chin Monday and was being similarly battered by investors Tuesday because of post-earnings analyst price target cuts. Following second-quarter results that disappointed many investors, several analysts recalibrated their takes on BioNTech stock Tuesday.